CERT * Stock Overview
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Certara, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$359.40 |
| 52 Week High | US$360.00 |
| 52 Week Low | US$302.00 |
| Beta | 1.57 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -0.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| CERT * | MX Healthcare Services | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how CERT * performed against the MX Healthcare Services industry.
Return vs Market: Insufficient data to determine how CERT * performed against the MX Market.
Price Volatility
| CERT * volatility | |
|---|---|
| CERT * Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: CERT * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CERT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,177 | Bill Feehery | www.certara.com |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers’ new drugs through the regulatory submission process and into the market.
Certara, Inc. Fundamentals Summary
| CERT * fundamental statistics | |
|---|---|
| Market cap | Mex$69.64b |
| Earnings (TTM) | Mex$266.15m |
| Revenue (TTM) | Mex$6.06b |
261.7x
P/E Ratio11.5x
P/S RatioIs CERT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERT * income statement (TTM) | |
|---|---|
| Revenue | US$335.64m |
| Cost of Revenue | US$132.58m |
| Gross Profit | US$203.07m |
| Other Expenses | US$188.34m |
| Earnings | US$14.73m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 08, 2023
| Earnings per share (EPS) | 0.092 |
| Gross Margin | 60.50% |
| Net Profit Margin | 4.39% |
| Debt/Equity Ratio | 27.1% |
How did CERT * perform over the long term?
See historical performance and comparison